The 65% Problem.
Most cross-border patients return home with no structured follow-up. The industry treats this as standard practice. We treat it as the most expensive design flaw in international healthcare.
MediGence's Point of View
If you want to knowwhat we'd do for you – readwhat we believe.
We publish thinking on the structural questions in international healthcare that the rest of the industry treats as immovable. None of this is gated. All of it is what we'd say in the first conversation.
Why Estimates Beat Budgets.
Every cost overrun starts with an approval based on an estimate. Until pricing becomes pre-confirmed, every international healthcare programme is operating on a guess.
Configurability Is Not a Feature.
It is the only commercial structure that lets one platform serve insurers, employers, and brokers without forcing them into the same product. Why CCP is built around it.
What Outcome Data Would Reveal.
Insurers measure utilisation. Employers measure absenteeism. Nobody measures whether the treatment worked. The conversation that begins when outcome data finally exists.
The Co-Brand Question.
Why MediGence runs invisibly under the insurer's brand – and why this is a strategic choice, not a marketing one.
Curiosity Over Coverage.
Why the most successful international healthcare conversations we have do not start with what we offer – they start with a question the insurer has been quietly avoiding.
Begin a Conversation
Insights are not gated. The first call is not pitched.
We do not present at you. We listen to what your organisation actually needs, and we tell you honestly whether CCP is the right fit.